82 results on '"Hayashi T"'
Search Results
2. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study
3. 74P Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
4. 1439P Phase II study to evaluate feasibility and safety of oral nutritional supplementation with high density liquid diet after total gastrectomy for patients with gastric cancer
5. Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour
6. Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
7. Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
8. Nrf2 expression in surgically resected lung adenocarcinomas: Its association with clinicopathologic features and driver oncogene alterations
9. Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
10. Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
11. Comprehensive mRNA-based screen for tyrosine kinase fusions and a de novo alternative transcription initiation site in soft tissue sarcomas
12. The PD-L1 expression in surgically resected lung adenocarcinoma: Its correlations with the prognosis, driver oncogene alterations and clinicopathological features
13. Lipid cell change in urothelial carcinoma: Signs of tumor aggression and the worst prognosis among the variants
14. The difference of risk factor for gastric cancer surgery between elderly and non-elderly patients
15. Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?
16. Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?
17. Comprehensive analysis for immune profiles of tumor microenvironment in non-small cell lung cancers: Prognostic effect of immunomodulatory molecules
18. Comprehensive analysis for immune profiles of tumor microenvironment in lung adenocarcinomas: Prognostic effect of immunomodulatory molecules
19. Feasibility study of preoperative chemotherapy for esophageal cancer with naso-gastric ED tube for patients with difficulty of oral ingestion
20. Optimal cutoff of histological response by neoadjuvant chemotherapy for gastric cancer
21. Priority of lymphadenectomy for each station in elderly patients with middle to distal advanced gastric cancer
22. Impact of preoperative sarcopenia on overall survival in gastric cancer surgery
23. Anti-tumor activity of tyrosine kinase inhibitors in alveolar soft part sarcoma
24. Practical screening system of oncogenic driver fusions in lung adenocarcinoma, using the NanoString nCounter
25. 430P - Emetic risk of carboplatin plus pemetrexed is higher than that of carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis
26. 423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
27. 411P - Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour
28. 69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
29. 63P - Nrf2 expression in surgically resected lung adenocarcinomas: Its association with clinicopathologic features and driver oncogene alterations
30. 778P - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
31. 5-ALA administration for photodynamic diagnosis of peritoneal metastases due to advanced gastric cancer: A randomised, double-blind, multicentre phase I/II study
32. A pooled analysis evaluating the combination antiemetic therapy on chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk
33. 258P First-line chemotherapies with FOLFIRINOX or gemcitabine plus nab-paclitaxel for unresectable pancreatic ductal adenocarcinoma in Japanese daily clinical practice
34. Biomarker analysis to predict the pathological response of locally advanced gastric cancer to neoadjuvant chemotherapy: an exploratory study of the randomized phase II COMPASS trial
35. Is the overall survival after hormone therapy for hormone-receptor-positive, HER2-negative metastatic breast cancer still better than for triple-negative metastatic breast cancer?
36. 454P - The PD-L1 expression in surgically resected lung adenocarcinoma: Its correlations with the prognosis, driver oncogene alterations and clinicopathological features
37. 412P - Comprehensive mRNA-based screen for tyrosine kinase fusions and a de novo alternative transcription initiation site in soft tissue sarcomas
38. 244P - Lipid cell change in urothelial carcinoma: Signs of tumor aggression and the worst prognosis among the variants
39. 1358P - Comprehensive analysis for immune profiles of tumor microenvironment in non-small cell lung cancers: Prognostic effect of immunomodulatory molecules
40. 692P - The difference of risk factor for gastric cancer surgery between elderly and non-elderly patients
41. 657P - Can preoperative diagnosis select therapeutic target of neoadjuvant chemotherapy for gastric cancer?
42. 639P - Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?
43. P-055 Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic risk
44. 376PD The multicenter, prospective observational study of the 5-HT3 receptor antagonist and dexamethasone as prophylaxis of chemotherapy- induced nausea and vomiting (CINV) in moderately emetic chemotherapy (MEC) for solid tumors
45. 493P - Anti-tumor activity of tyrosine kinase inhibitors in alveolar soft part sarcoma
46. 225P - Feasibility study of preoperative chemotherapy for esophageal cancer with naso-gastric ED tube for patients with difficulty of oral ingestion
47. 214P - Priority of lymphadenectomy for each station in elderly patients with middle to distal advanced gastric cancer
48. 215P - Optimal cutoff of histological response by neoadjuvant chemotherapy for gastric cancer
49. 211P - Impact of preoperative sarcopenia on overall survival in gastric cancer surgery
50. 24 - Practical screening system of oncogenic driver fusions in lung adenocarcinoma, using the NanoString nCounter
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.